Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ZOL Reduced Recurrence at All Sites<br />
First event per patient, n<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
2<br />
10<br />
10<br />
41<br />
20<br />
No ZOL vs ZOL<br />
No ZOL ZOL<br />
(n = 904) (n = 899)<br />
DFS = Disease-free survival; ITT = Intent-to-treat; ZOL = Zoledronic acid.<br />
<strong>Gnant</strong> M, et al. Presented at: ASCO 20<strong>08</strong>. Chicago, IL. Abstract LBA4.<br />
0<br />
9<br />
6<br />
29<br />
10<br />
Death without prior recurrence<br />
Secondary malignancy<br />
Contralateral breast cancer<br />
Distant recurrence<br />
Locoregional recurrence<br />
14
Change language